Chimerix (CMRX) Begins Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Chimerix (CMRX) Begins Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

After-Hours Stock Movers 04/28: (RRD) (GOOGL) (WW) Higher; (IRBR) (F) (FEYE) Lower (more...)

April 28, 2020 5:46 PM EDT

Today's After-Hours Stock Movers

RR Donnelley (NYSE: RRD) 40% HIGHER; reported Q1 EPS of $0.33, $0.37 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.41 billion versus the consensus estimate of $1.38 billion.

Chimerix (NASDAQ: CMRX) 22.5% HIGHER; announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.... More

Chimerix (CMRX) Receives FDA Clearance for Rolling Submission of NDA for Brincidofovir as Medical Countermeasure for Smallpox

April 28, 2020 5:06 PM EDT

Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.... More